Luye Pharma Group Ltd. (FRA:LUP)

Market Cap	963.01M +12.6%
Revenue (ttm)	768.16M +4.1%
Net Income	75.34M +31.1%
EPS	0.02 +26.7%
Shares Out	n/a
PE Ratio	12.78
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.2340
Previous Close	0.2360
Day's Range	0.2340 - 0.2360
52-Week Range	0.2300 - 0.4820
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema and edema caused by traum...

• Industry: Pharmaceutical Preparations
• Founded: 1994
• Employees: 5,221
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LUP

Financial Performance

In 2025, Luye Pharma Group's revenue was 6.31 billion, an increase of 4.07% compared to the previous year's 6.06 billion. Earnings were 618.75 million, an increase of 31.12%.

Financial numbers in CNY